Ranbxy Pharmaceuticals

Overall Rating: star ratingstar ratingstar ratingstar ratingstar rating[5/5]Total Votes [ 7 ]  
Rate this page:
Ranbaxy is among the predominant pharmaceutical companies in India and was founded in 1961. Ranbaxy is a research based pharma giant and became a public limited company in 1973. The company has gained significant popularity in India as well as abroad due to its large portfolio and cost-effective medicines that are trusted by medical professionals across the world.

Ranbaxy was recently ranked among the top 10 international pharmaceutical companies in the world by dint of the fact that it has a powerful presence in as many as 23 pharma markets in the world across 49 countries.

Ranbaxy is also reputed for its 11 state-of-the-art manufacturing facilities in countries like China, India, Brazil, South Africa, and Nigeria. The company has also won several awards and recognitions for its pioneering initiatives in the developing markets of the world. Ranbaxy is also a member of the Indian Pharmaceutical Alliance and Organization of Pharmaceutical Producers of India. In the present scenario Ranbaxy commands more than 5% share of the Indian pharmaceutical market. The company registered sales of US$ 286 million in 2006 during which it grew by more than 17%. Ranbaxy’s product portfolio is diverse and includes drugs that cater to nutrition, infectious diseases, gastro-enteritis, pain management, cardiovascular ailments, dermatology, and central nervous system related ailments.

Ranbaxy’s operations in India are designed under as many as 9 SBUs which take care of the various categories of medicines and drugs that are manufactured by Ranbaxy. The company is especially well-known for having the highest research and development (R&D) budget among pharma companies in the world which is as high as US$ 100 million. Ranbaxy emphasizes R&D to a great extent and considers research its USP based on which it seeks to attain long-term sustainability as well as a competitive edge. Towards this end, Ranbaxy has employed 1000 scientists who are responsible for the cutting-edge research and products put forth by Ranbaxy in India.

Ranbaxy India operations are handled by 2,500 employees and the company’s market share in India is worth around US$6 billion. In India, Ranbaxy is most reputed for its research and products in the realm of diabetes, psychiatry, and dermatology. The main strength areas of Ranbaxy India are:
  • It is a leader in Novel Drug Delivery System (NDDS) products. Some of the most important brands under this category are Cifran OD, Sporidex AF, and Zanocin OD.

  • It has extremely powerful brand-awareness capabilities and as a result as many as 20 brands owned by the company feature in the 300 most well-known brands of the pharma industry in India. The 5 most well-known brands under Ranbaxy are Zanocin, Sporidex, Volini, Cifran, and Mox.
The company had the special distinction of being recognized as the “Best in Class” pharma company in an AC Nielsen ORG MARG Report that was published in June, 2004. Ranbaxy also conducts as many as 2000 interface initiatives and publishes around 20 medical papers on an annual basis.

In order to expand its presence in India as well as across the world, Ranbaxy is focusing on domains such as knowledge management, marketing initiatives, advisories, market intelligence, post-marketing monitoring studies, and medical awareness in a big way. These initiatives have led to Ranbaxy’s strong rapport with medical professionals.

The following are the products and services that Ranbaxy plans to leverage upon in the near future as far as its Indian operations are concerned:

  • Biological formulations like Vaxigrip (vaccine for Flu) and Verorab (vaccine for Rabies) that require a great deal of awareness building are in-licensed and are being co-promoted with Sanofi Pastuer.

  • An entire range of products has been recently introduced to cater to the dermatology segment.

  • Anti-infectives such as Cilanem and Faronem have been launched for the first time in India. Ranbaxy is trying to promote the concept of Penems/Carbapenmens on a local basis.

  • Metered Dose Inhalers have also been introduced in the respiratory category.

Ranbaxy can be contacted at:

Ranbaxy Laboratories Limited
Corporate Office, Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: +91- 124- 4135000
Email: mukta.v@ranbaxy.com

Last Updated on 21/06/2011